Physician profile
Polina Kagan
NPI 1508855792
$3,224.99
in general payments reported to CMS, 2019-2025
27 companies · $504 in 2025
The $504 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $264 · 2021: $493 · 2022: $637 · 2023: $551 · 2024: $262 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.23 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.37 | 2019-2023 | |
| Exeltis, USA INC. | $483.02 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $396.37 | 2021-2025 | |
| Coopersurgical, INC. | $156.18 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $155.73 | 2019-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $153.16 | 2019-2022 | |
| Avion Pharmaceuticals | $143.23 | 2019-2022 | |
| Daiichi Sankyo INC. | $139.59 | 2019-2022 | |
| Evofem Biosciences, INC. | $126.29 | 2021-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $101.71 | 2021-2023 | Nexplanon |
| Astellas Pharma US INC | $98.40 | 2020-2024 | Veozah |
| Pfizer INC. | $97.07 | 2019-2024 | |
| Shield Therapeutics INC | $93.76 | 2023-2025 | Accrufer |
| Biogen, INC. | $74.90 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $58.31 | 2022-2024 | Twirla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $54.33 | 2019-2020 | |
| Myovant Sciences INC. | $48.33 | 2021 | |
| Amgen INC. | $45.27 | 2019-2020 | |
| Meditrina | $42.02 | 2023-2025 | |
| Exact Sciences Corporation | $29.65 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $26.44 | 2025 | Myfembree |
| Allergan, INC. | $24.62 | 2019 | |
| Hologic Sales and Service, LLC | $22.56 | 2025 | Aptima |
| Millicent US INC | $20.54 | 2024 | Intrarosa |
| Lsi Solutions INC | $20.40 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.00 | 2019 | |
| Scynexis, INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polina Kagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.